The site of the Media Sphera Publishers contains materials intended solely for healthcare professionals.
By closing this message, you confirm that you are a certified medical professional or a student of a medical educational institution.

Login
EN
+7 (495) 482-4118
+7 (495) 482-0604
+8 800 101-59-87
  • (toll-free number for subscriptions)
    Mon-Fri from 10 a.m. to 6 p.m.

  • © 1998-2025
+7 (495) 482-43-29
EN
All journals
Journal
Year
Year
Search result: 0

Salimzyanov K.I.

P.A. Herzen Moscow Oncology Research Institute — Branch of the National Medical Radiology Research Center

Ryabov A.B.

P.A. Herzen Moscow Oncology Research Institute — Branch of the National Medical Radiology Research Center

Khomyakov V.M.

P.A. Herzen Moscow Oncology Research Institute — Branch of the National Medical Radiology Research Center

Bolotina L.V.

P.A. Herzen Moscow Oncology Research Institute — Branch of the National Medical Radiology Research Center

Sobolev D.D.

P.A. Herzen Moscow Oncology Research Institute — Branch of the National Medical Radiology Research Center

Kaprin A.D.

P.A. Herzen Moscow Oncology Research Institute — Branch of the National Medical Radiology Research Center;
A. Tsyb Medical Radiological Research Center — Branch of the National Medical Radiological Research Center;
Peoples’ Friendship University of Russia named after Patrice Lumumba

Immune checkpoint inhibitors as a component of perioperative therapy in patients with resectable esophageal and cardioesophageal junction cancer

Authors:

Salimzyanov K.I., Ryabov A.B., Khomyakov V.M., Bolotina L.V., Sobolev D.D., Kaprin A.D.

More about the authors

Journal: P.A. Herzen Journal of Oncology. 2024;13(5): 62‑68

DOI: 10.17116/onkolog20241305162

Views: 305

Downloaded: 2

Buy for 200₽
Contact the author
Table of contents

To cite this article:

Salimzyanov KI, Ryabov AB, Khomyakov VM, Bolotina LV, Sobolev DD, Kaprin AD. Immune checkpoint inhibitors as a component of perioperative therapy in patients with resectable esophageal and cardioesophageal junction cancer. P.A. Herzen Journal of Oncology. 2024;13(5):62‑68. (In Russ.)
https://doi.org/10.17116/onkolog20241305162

Подписка 2025 (P.A. Herzen Journal of Oncology)
МСФ на ЯМ
Close metadata
Recommended articles:
Unco­ntrolled inhi­bition of checkpoints. P.A. Herzen Journal of Onco­logy. 2024;(2):67-73
Modern treatment methods for patients with liver meta­stases from uveal mela­noma. P.A. Herzen Journal of Onco­logy. 2024;(2):74-84
Methodological aspe­cts of complex therapy of loca­lly adva­nced rectal cancer. P.A. Herzen Journal of Onco­logy. 2024;(3):20-26
Surgical treatment and prognostic factors in peri­hilar tumors. Piro­gov Russian Journal of Surgery. 2024;(2):14-23
Indo­cyanine green in delayed esophageal reco­nstruction after previous exti­rpation. Piro­gov Russian Journal of Surgery. 2024;(2-2):67-72
Poly(ADP-ribose) poly­merase (PARP) inhi­bitors for BRCA-associated early triple-negative breast cancer: progress and future hopes. Medi­cal Technologies. Asse­ssment and Choice. 2024;(1):91-100
Treatment of primary mali­gnant mela­noma of the esophagus. Piro­gov Russian Journal of Surgery. 2024;(4):118-124
Fluorescein angiography with indo­cyanine green in mini­mally inva­sive surgery for cancer of the esophagus and cardia. Endo­scopic Surgery. 2024;(2):19-26
Tumor infi­ltrating lymphocytes (TILs) in triple nega­tive breast cancer. Russian Journal of Archive of Pathology. 2024;(3):5-11
The impact of endo­scopy in upper gastrointestinal tract cancer screening programs. Russian Journal of Evidence-Based Gastroenterology. 2024;(2):79-88

To date, the prognosis of patients with resectable forms of esophageal cancer remains unsatisfactory; therefore, over the past 5 years, interest in the use of immunotherapy as a component of combined treatment has increased. Immune checkpoint inhibitors have been used in unresectable and metastatic esophageal cancer for several years. In recent years, neoadjuvant immunotherapy has achieved impressive rates of tumor pathomorphological response to treatment in patients with early-stage non-small cell lung cancer, melanoma, bladder and colorectal cancers. In this review, we consider the results and rationale of clinical trials that may further lead to the introduction into clinical practice of immune checkpoint inhibitors as a component of combination treatment for resectable esophageal cancer. Data from ongoing trials evaluating long-term outcomes are awaited to answer the question regarding the efficacy of immunotherapy and to determine the most appropriate therapy regimen.

Keywords:

esophageal cancer
cardioesophageal cancer
immunotherapy
immune checkpoint inhibitors
neoadjuvant therapy
adjuvant therapy

Authors:

Salimzyanov K.I.

P.A. Herzen Moscow Oncology Research Institute — Branch of the National Medical Radiology Research Center

Ryabov A.B.

P.A. Herzen Moscow Oncology Research Institute — Branch of the National Medical Radiology Research Center

Khomyakov V.M.

P.A. Herzen Moscow Oncology Research Institute — Branch of the National Medical Radiology Research Center

Bolotina L.V.

P.A. Herzen Moscow Oncology Research Institute — Branch of the National Medical Radiology Research Center

Sobolev D.D.

P.A. Herzen Moscow Oncology Research Institute — Branch of the National Medical Radiology Research Center

Kaprin A.D.

P.A. Herzen Moscow Oncology Research Institute — Branch of the National Medical Radiology Research Center;
A. Tsyb Medical Radiological Research Center — Branch of the National Medical Radiological Research Center;
Peoples’ Friendship University of Russia named after Patrice Lumumba

Received:

23.07.2023

Accepted:

31.07.2023

List of references:

  1. Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, Bray F. Global Cancer Statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021;71(3):209-249.  https://doi.org/10.3322/CAAC.21660
  2. Kaprin AD, Starinskii VV, Shakhzadova AO, eds. Malignant neoplasms in Russia in 2020 (morbidity and mortality). M.: MNIOI im. P.A. Gertzena — filial FGBU «NMITs radiologii» Minzdrava Rossii; 2021. (In Russ.).
  3. Morgan E, Soerjomataram I, Rumgay H, Coleman HG, Thrift AP, Vignat J, Laversanne M, Ferlay J, Arnold M. The global landscape of esophageal squamous cell carcinoma and esophageal adenocarcinoma incidence and mortality in 2020 and projections to 2040: new estimates from GLOBOCAN 2020. Gastroenterology. 2022;163(3):649-658.e2.  https://doi.org/10.1053/j.gastro.2022.05.054
  4. Shapiro J, van Lanschot JJB, Hulshof MCCM, et al. Neoadjuvant chemoradiotherapy plus surgery versus surgery alone for oesophageal or junctional cancer (CROSS): long-term results of a randomised controlled trial. Lancet Oncol. 2015;16(9):1090-1098. https://doi.org/10.1016/S1470-2045(15)00040-6
  5. Yang H, Liu H, Chen Y, et al. Neoadjuvant chemoradiotherapy followed by surgery versus surgery alone for locally advanced squamous cell carcinoma of the esophagus (NEOCRTEC5010): a phase III multicenter, randomized, open-label clinical trial. J Clin Oncol. 2018;36(27):2796-2803. https://doi.org/10.1200/JCO.2018.79.1483
  6. Tryakin AA, Besova NS, Volkov NM, Gamayunov SV, Kononets PV, Levchenko EV, Ter-Ovanesov MD, Chernykh MV. Prakticheskie rekomendatsii po lekarstvennomu lecheniyu raka pishchevoda i pishchevodno-zheludochnogo perekhoda. Zlokachestvennye Opukholi. Practical Recommendations RUSSCO #3s2. 2022;12(3s2-1):366-381. (In Russ.). https://doi.org/10.18027/2224-5057-2022-12-3s2-366-381
  7. Doi T, Piha-Paul SA, Jalal SI, Saraf S, Lunceford J, Koshiji M, Bennouna J. Safety and antitumor activity of the anti-programmed death-1 antibody pembrolizumab in patients with advanced esophageal carcinoma. J Clin Oncol. 2018;36(1):61-67.  https://doi.org/10.1200/JCO.2017.74.9846
  8. Shah MA, Kojima T, Hochhauser D, et al. Efficacy and safety of pembrolizumab for heavily pretreated patients with advanced, metastatic adenocarcinoma or squamous cell carcinoma of the esophagus: the Phase 2 KEYNOTE-180 Study. JAMA Oncol. 2019;5(4):546-550.  https://doi.org/10.1001/JAMAONCOL.2018.5441
  9. Kojima T, Shah MA, Muro K, et al. Randomized phase III KEYNOTE-181 study of pembrolizumab versus chemotherapy in advanced esophageal cancer. J Clin Oncol. 2020;38(35):4138-4148. https://doi.org/10.1200/JCO.20.01888
  10. Forde PM, Chaft JE, Smith KN, et al. Neoadjuvant PD-1 blockade in resectable lung cancer. N Engl J Med. 2018;378(21):1976-1986. https://doi.org/10.1056/NEJMOA1716078
  11. Huang AC, Orlowski RJ, Xu X, et al. A single dose of neoadjuvant PD-1 blockade predicts clinical outcomes in resectable melanoma. Nat Med. 2019;25(3):454-461.  https://doi.org/10.1038/S41591-019-0357-Y
  12. Powles T, Kockx M, Rodriguez-Vida A, et al. Clinical efficacy and biomarker analysis of neoadjuvant atezolizumab in operable urothelial carcinoma in the ABACUS trial. Nat Med. 2019;25(11):1706-1714. https://doi.org/10.1038/S41591-019-0628-7
  13. Chalabi M, Fanchi LF, Dijkstra KK, et al. Neoadjuvant immunotherapy leads to pathological responses in MMR-proficient and MMR-deficient early-stage colon cancers. Nat Med. 2020;26(4):566-576.  https://doi.org/10.1038/S41591-020-0805-8
  14. Lu Z, Zou J, Li S, et al. Epigenetic therapy inhibits metastases by disrupting premetastatic niches. Nature. 2020;579(7798):284-290.  https://doi.org/10.1038/S41586-020-2054-X
  15. Li C, Zhao S, Zheng Y, et al. Preoperative pembrolizumab combined with chemoradiotherapy for oesophageal squamous cell carcinoma (PALACE-1). Eur J Cancer. 2021;144:232-241.  https://doi.org/10.1016/J.EJCA.2020.11.039
  16. Liu BW, Shang QX, Yang YS, Chen LQ. Efficacy and safety of PD-1/PD-L1 inhibitor combined with chemotherapy versus chemotherapy alone in the treatment of advanced gastric or gastroesophageal junction adenocarcinoma: a systematic review and meta-analysis. Front Oncol. 2023;13:1077675. https://doi.org/10.3389/FONC.2023.1077675
  17. Van Den Ende T, De Clercq NC, Van Berge Henegouwen MI, et al. Neoadjuvant chemoradiotherapy combined with atezolizumab for resectable esophageal adenocarcinoma: a single-arm phase II feasibility trial (PERFECT). Clin Cancer Res. 2021;27(12):3351-3359. https://doi.org/10.1158/1078-0432.CCR-20-4443
  18. Eyck BM, Van Lanschot JJB, Hulshof MCCM, et al.; CROSS Study Group. Ten-year outcome of neoadjuvant chemoradiotherapy plus surgery for esophageal cancer: the randomized controlled CROSS trial. J Clin Oncol. 2021;39(18):1995-2004. https://doi.org/10.1200/JCO.20.03614
  19. Mansukhani S, Davidson M, Gillbanks A, et al. Iconic: peri-operative immuno-chemotherapy in operable oesophageal and gastric cancer. J Clin Oncol. 2018;36(15_suppl):TPS4139. https://doi.org/10.1200/JCO.2018.36.15_SUPPL.TPS4139
  20. Al-Batran S-E, Lorenzen S, Thuss-Patience PC, et al. Surgical and pathological outcome, and pathological regression, in patients receiving perioperative atezolizumab in combination with FLOT chemotherapy versus FLOT alone for resectable esophagogastric adenocarcinoma: interim results from DANTE, a randomized, multicenter, phase IIb trial of the FLOT-AIO German Gastric Cancer Group and Swiss SAKK. J Clin Oncol. 2022;40(16_suppl):4003. https://doi.org/10.1200/JCO.2022.40.16_SUPPL.4003
  21. He W, Leng X, Mao T, et al. Toripalimab plus paclitaxel and carboplatin as neoadjuvant therapy in locally advanced resectable esophageal squamous cell carcinoma. Oncologist. 2022;27(1):e18-e28.  https://doi.org/10.1093/ONCOLO/OYAB011
  22. Fukuoka E, Yamashita K, Tanaka T, et al. Neoadjuvant chemotherapy increases PD-L1 expression and CD8+ tumor-infiltrating lymphocytes in esophageal squamous cell carcinoma. Anticancer Res. 2019;39(8):4539-4548. https://doi.org/10.21873/ANTICANRES.13631
  23. Ilie M, Long-Mira E, Bence C, et al. Comparative study of the PD-L1 status between surgically resected specimens and matched biopsies of NSCLC patients reveal major discordances: a potential issue for anti-PD-L1 therapeutic strategies. Ann Oncol. 2016;27(1):147-153.  https://doi.org/10.1093/ANNONC/MDV489
  24. Park R, Da Silva LL, Saeed A. Immunotherapy predictive molecular markers in advanced gastroesophageal cancer: MSI and beyond. Cancers (Basel). 2021;13(7):1715. https://doi.org/10.3390/CANCERS13071715
  25. Pietrantonio F, Miceli R, Raimondi A, et al. Individual patient data meta-analysis of the value of microsatellite instability as a biomarker in gastric cancer. J Clin Oncol. 2019;37(35):3392-3400. https://doi.org/10.1200/JCO.19.01124
  26. Polom K, Marrelli D, Roviello G, Pascale V, Voglino C, Rho H, Marini M, Macchiarelli R, Roviello F. Molecular key to understand the gastric cancer biology in elderly patients - the role of microsatellite instability. J Surg Oncol. 2017;115(3):344-350.  https://doi.org/10.1002/JSO.24513
  27. Cancer Genome Atlas Research Network; Analysis Working Group: Asan University; BC Cancer Agency; Brigham and Women’s Hospital; Broad Institute; Brown University; Case Western Reserve University; Dana-Farber Cancer Institute; Duke University; Greater Poland Cancer Centre; et al. Integrated genomic characterization of oesophageal carcinoma. Nature. 2017;541(7636):169-175.  https://doi.org/10.1038/NATURE20805
  28. André T, Tougeron D, Piessen G, et al. Neoadjuvant nivolumab plus ipilimumab and adjuvant nivolumab in localized deficient mismatch repair/microsatellite instability - high gastric or esophagogastric junction adenocarcinoma: the GERCOR NEONIPIGA Phase II Study. J Clin Oncol. 2023;41(2):255-265.  https://doi.org/10.1200/JCO.22.00686
  29. Kwon M, An M, Klempner SJ, Lee H, Kim KM, Sa JK, et al. Determinants of response and intrinsic resistance to pd-1 blockade in microsatellite instability-high gastric cancer. Cancer Discov. 2021;11(9):2168-2185. https://doi.org/10.1158/2159-8290.CD-21-0219
  30. Chida K, Kawazoe A, Kawazu M, et al. A low tumor mutational burden and PTEN mutations are predictors of a negative response to PD-1 blockade in MSI-H/dMMR gastrointestinal tumors. Clin Cancer Res. 2021;27(13):3714-3724. https://doi.org/10.1158/1078-0432.CCR-21-0401
  31. Cao W, Xing H, Li Y, Tian W, Song Y, Jiang Z, Yu J. Claudin18.2 is a novel molecular biomarker for tumor-targeted immunotherapy. Biomark Res. 2022;10(1):38.  https://doi.org/10.1186/S40364-022-00385-1
  32. Lengyel CG, Hussain S, Seeber A, et al. FGFR pathway inhibition in gastric cancer: the golden era of an old target? Life (Basel). 2022;12(1):81.  https://doi.org/10.3390/LIFE12010081
  33. Wang H, Li S, Liu T, Chen J, Dang J. Neoadjuvant immune checkpoint inhibitor in combination with chemotherapy or chemoradiotherapy in resectable esophageal cancer: a systematic review and meta-analysis. Front Immunol. 2022;13:998620. https://doi.org/10.3389/FIMMU.2022.998620
  34. Wang H, Song C, Zhao X, Deng W, Dong J, Shen W. Evaluation of neoadjuvant immunotherapy and traditional neoadjuvant therapy for resectable esophageal cancer: a systematic review and single-arm and network meta-analysis. Front Immunol. 2023;14:1170569. https://doi.org/10.3389/FIMMU.2023.1170569
  35. Siewert JR, Ott K. Are squamous and adenocarcinomas of the esophagus the same disease? Semin Radiat Oncol. 2007;17(1):38-44.  https://doi.org/10.1016/J.SEMRADONC.2006.09.007
  36. Salem ME, Puccini A, Xiu J, Raghavan D, Lenz HJ, Korn WM, Shields AF, Philip PA, Marshall JL, Goldberg RM. Comparative molecular analyses of esophageal squamous cell carcinoma, esophageal adenocarcinoma, and gastric adenocarcinoma. Oncologist. 2018;23(11):1319-1327. https://doi.org/10.1634/THEONCOLOGIST.2018-0143
  37. Blum Murphy M, Xiao L, Patel VR, et al. Pathological complete response in patients with esophageal cancer after the trimodality approach: the association with baseline variables and survival - the University of Texas MD Anderson Cancer Center experience. Cancer. 2017;123(21):4106-4113. https://doi.org/10.1002/CNCR.30953
  38. Kelly RJ, Ajani JA, Kuzdzal J, et al. Adjuvant nivolumab in resected esophageal or gastroesophageal junction cancer. N Engl J Med. 2021;384(13):1191-1203. https://doi.org/10.1056/NEJMOA2032125
  39. Mamdani H, Schneider B, Perkins SM, et al. A phase II trial of adjuvant durvalumab following trimodality therapy for locally advanced esophageal and gastroesophageal junction adenocarcinoma: a big ten cancer research consortium study. Front Oncol. 2021;11:736620. https://doi.org/10.3389/FONC.2021.736620

Close metadata

Contact the author
Email
Message
The publishing house "Media Sphere" does not provide treatment services, does not give recommendations on contacting medical institutions and specific specialists, on the prescription of medicines and dietary supplements.

Email Confirmation

An email was sent to test@gmail.com with a confirmation link. Follow the link from the letter to complete the registration on the site.

Email Confirmation

Contact us
If you have any questions, complaints or suggestions, please use this feedback form.
Email
Message
The publishing house "Media Sphere" does not provide treatment services, does not give recommendations on contacting medical institutions and specific specialists, on the prescription of medicines and dietary supplements.
Submit Application

You can become an author of one of our magazines, send a request and we will consider it in during the day.

Name
Phone
E-mail
Message
Login
Registration
E-mail
Password
Forgot Password?

Log in to the site using your account in one of the services

Password recovery
E-mail
Login
Register


We use cооkies to improve the performance of the site. By staying on our site, you agree to the terms of use of cооkies. To view our Privacy and Cookie Policy, please. click here.